🇺🇸 FDA
Pipeline program

JSB462

CJSB462A11101

Phase 1 small_molecule active

Quick answer

JSB462 for Metastatic Prostate Cancer (mCRPC) is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Metastatic Prostate Cancer (mCRPC)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials